What circumstances would make brolucizumab your anti-VEGF drug of choice?

Click here to read the Cover Story, "Successful retinal injection practice depends on clinical efficiency, patient satisfaction."

Exudative age-related macular degeneration is the leading cause of blindness in the developed world in people older than 65 years of age. Numerous intravitreal anti-VEGF medications (pegaptanib, bevacizumab, ranibizumab, aflibercept and brolucizumab) have been developed as therapeutic agents to suppress activity and improve visual outcomes. Although the therapies are effective, significant economic and caregiver burdens exist due to repeated intravitreal

Full Story →